The establishment of this interdisciplinary centre was made possible through grants from the Kristian Gerhard Jebsen Foundation and from the Faculty of Medicine and Dentistry, University of Bergen and Haukeland University Hospital. In addition, the researchers within the centre receives support from The Norwegian Cancer Society, The Norwegian Research Council the Bergen Research Foundation as well as the European Commission. The K.G. Jebsen BTRC and the University of Bergen-NorLux partnership fosters excellence in brain tumour research, amalgamating the expertise of scientists, clinical investigators and physicians in a virtual laboratory environment at the University of Bergen, The Haukeland University Hospital and Luxembourg Institute of Health (L.I.H.), Luxembourg. A stimulating research environment has been created allowing scientists to share ideas, resources and equipment in an atmosphere conductive to achieving excellence in molecular neuro-oncology research, scientific output and clinical research.
The primary goal of the Kristian Gerhard Jebsen Brain Tumour Research Centre is to provide better and more predictable treatment of patients with malignant brain tumors. This will be done by translating new important knowledge gained from our extensive research activities into clinical trials where scientists and health care clinicians work in partnership to translate laboratory findings into new or improved forms of therapy.
We focus on primary brain tumours as well as metastatic tumours to the brain. Our research activities within the NorLux laboratories focus on basic and translational research, where the aim is to understand better how brain tumors are initiated and to better delineate the mechanisms responsible for tumor growth. The K.G. Jebsen BTRC focuses on bringing this knowledge into the clinic.